Home > Insider Trading > Filing (0001576280-21-000020)

Filing Details

Accession Number:: 0001576280-21-000020
Form Type:: 4/A
Zero Holdings:: No
Publication Time:: 2021-02-17 17:22:45
Reporting Period:: 2021-02-04

Accepted Time:: 2021-02-17 17:22:45
Original Submission Date:: 2021-02-05
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1576280	Guardant Health Inc.	GH	Services-Medical Laboratories (8071)	454139254

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1753159	Amirali Talasaz	505 Penobscot Drive Redwood City CA 94063	Chairman, President And Coo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2021-02-04	17,988	$158.76	2,396,846	No	4	S	Direct
Common Stock	Disposition	2021-02-04	13,874	$159.59	2,382,972	No	4	S	Direct
Common Stock	Disposition	2021-02-04	1,315	$160.12	2,381,657	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Footnotes

These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $158.07 to $159.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
This amendment corrects minor errors regarding share amounts and/or prices.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $159.07 to $160.055, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $160.07 to $160.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Reflects updated direct holdings as of 02/04/2021 after giving effect to the corrections to the share amounts.